{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-002832","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.662571+00:00","generated_at":"2026-05-27T23:30:37.916834+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kairos Pharma closes $3.5M PIPE offering of pre-funded units and warrants","bullets":["Sold 2,500,000 Pre-Funded Units at $1.399/unit, raising gross proceeds of $3,497,500.","Each Pre-Funded Unit includes a pre-funded warrant (exercise $0.001) and 1.5 common warrants (exercise $1.40).","Amended agreement requires shareholder approval before issuing >19.99% of common stock.","Placement agents Boustead and D. Boral receive 8% cash commission plus warrants for 175,000 shares at $1.40.","Offering closed on January 16, 2025; securities sold under Section 4(a)(2) and Rule 506(b)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-002832","json":"https://secwatch.observer/filing/0001493152-25-002832.json","markdown":"https://secwatch.observer/filing/0001493152-25-002832.md","text":"https://secwatch.observer/filing/0001493152-25-002832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225002832/0001493152-25-002832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225002832/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T23:30:37.916834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}